Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan
Kaori Mukai Robert Cost Xin Sheen Zhang Emily Condiff Joanne Cotton Xiaohua Liu Ekaterina Boudanova Björn Niebel Peter Piepenhagen Xinming Cai Anna Park Qun Zhou a Immunology & Inflammation Research,Sanofi,Cambridge,MA,USAb Large Molecules Research,Sanofi,Cambridge,MA,USAc Translational In Vivo Models Research,Sanofi,Cambridge,MA,USAd CMC Bioanalytics,Sanofi,Framingham,USAe Large Molecules Research,Sanofi R&D Ghent,Ghent,Belgium
DOI: https://doi.org/10.1080/19420862.2024.2415333
2024-10-22
mAbs
Abstract:Recent developments in targeted protein degradation have provided great opportunities to eliminating extracellular protein targets using potential therapies with unique mechanisms of action and pharmacology. Among them, Lysosome-Targeting Chimeras (LYTACs) acting through mannose 6-phosphate receptor (M6PR) have been shown to facilitate degradation of several soluble and membrane-associated proteins in lysosomes with high efficiency. Herein we have developed a novel site-specific antibody conjugation approach to generate antibody mannose 6-phosphate (M6P) conjugates. The method uses a high affinity synthetic M6P glycan, bisM6P, that is coupled to an Fc-engineered antibody NNAS. This mutant without any effector function was generated by switching the native glycosylation site from position 297 to 298 converting non-sialylated structures to highly sialylated N-glycans. The sialic acid of the glycans attached to Asn298 in the engineered antibody was selectively conjugated to bisM6P without chemoenzymatic modification, which is often used for site-specific antibody conjugation through glycans. The conjugate is mainly homogeneous by analysis using mass spectrometry, typically with one or two glycans coupled. The M6P-conjugated antibody against a protein of interest (POI) efficiently internalized targeted soluble proteins, such as human tumor necrosis factor (TNF), in both cancer cell lines and human immune cells, through the endo-lysosomal pathway as demonstrated by confocal microscopy and flow cytometry. TNF in cell culture media was significantly depleted after the cells were incubated with the M6P-conjugated antibody. TNF internalization is mediated through M6PR, and it is correlated well with cell surface expression of cation-independent M6PR (CI-MPR) in immune cells. A significant amount of CI-MPR remains on the cell surface, while internalized TNF is degraded in lysosomes. Thus, the antibody-M6P conjugate is highly efficient in inducing internalization and subsequent lysosome-mediated protein degradation. Our platform provides a unique method for producing biologics-based degraders that may be used to treat diseases through event-driven pharmacology, thereby addressing unmet medical needs.
medicine, research & experimental